0001000228-22-000068 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 24, 2022	Oct. 24, 2022
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 24, 2022
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		135,547,575

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021
Current assets:
Cash and cash equivalents	$ 123	$ 118
Accounts receivable, net of reserves of $63 and $67	1,507	1,452
Inventories, net	1,818	1,861
Prepaid expenses and other	509	413
Total current assets	3,957	3,844
Property and equipment, net	354	366
Operating lease right-of-use assets	319	325
Goodwill	2,870	2,854
Other intangibles, net	635	668
Investments and other	399	424
Total assets	8,534	8,481
Current liabilities:
Accounts payable	957	1,054
Bank credit lines	107	51
Current maturities of long-term debt	4	11
Operating lease liabilities	72	76
Accrued expenses:
Payroll and related	330	385
Taxes	127	137
Other	549	593
Total current liabilities	2,146	2,307
Long-term debt	934	811
Deferred income taxes	37	42
Operating lease liabilities	271	268
Other liabilities	338	377
Total liabilities	3,726	3,805
Redeemable noncontrolling interests	563	613
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized, 135,258,887 outstanding on September 24, 2022 and 137,145,558 outstanding on December 25, 2021	1	1
Additional paid-in capital	0	0
Retained earnings	3,922	3,595
Accumulated other comprehensive loss	(312)	(171)
Total Henry Schein, Inc. stockholders' equity	3,611	3,425
Noncontrolling interests	634	638
Total stockholders' equity	4,245	4,063
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 8,534	$ 8,481

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021
Current assets:
Accounts receivable, reserves (in dollars)	$ 63	$ 67
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	135,258,887	137,145,558

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,067	$ 3,178	$ 9,276	$ 9,070
Cost of sales	2,153	2,266	6,444	6,376
Gross profit	914	912	2,832	2,694
Operating expenses:
Selling, general and administrative	648	657	2,010	1,906
Depreciation and amortization	45	44	137	133
Restructuring and integration costs	10	0	10	4
Operating income	211	211	675	651
Other income (expense):
Interest income	4	2	9	5
Interest expense	(11)	(7)	(27)	(20)
Other, net	1	0	1	1
Income before taxes, equity in earnings of affiliates and noncontrolling interests	205	206	658	637
Income taxes	(46)	(50)	(155)	(154)
Equity in earnings of affiliates	3	6	12	18
Gain on sale of equity investment	0	7	0	7
Net income	162	169	515	508
Less: Net income attributable to noncontrolling interests	(12)	(7)	(24)	(24)
Net income attributable to Henry Schein, Inc.	$ 150	$ 162	$ 491	$ 484
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 1.10	$ 1.16	$ 3.59	$ 3.44
Diluted (in dollars per share)	$ 1.09	$ 1.15	$ 3.55	$ 3.40
Weighted-average common shares outstanding:
Basic (in shares)	135,608,678	139,377,237	136,731,413	140,661,182
Diluted (in shares)	137,084,049	141,079,337	138,488,254	142,178,702

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 162	$ 169	$ 515	$ 508
Other comprehensive loss, net of tax:
Foreign currency translation loss	(89)	(40)	(176)	(40)
Unrealized gain from foreign currency hedging activities	11	4	20	5
Pension adjustment gain	1	0	1	1
Other comprehensive loss, net of tax	(77)	(36)	(155)	(34)
Comprehensive income	85	133	360	474
Comprehensive income attributable to noncontrolling interests:
Net income	(12)	(7)	(24)	(24)
Foreign currency translation loss	6	5	14	4
Comprehensive income attributable to noncontrolling interests	(6)	(2)	(10)	(20)
Comprehensive income attributable to Henry Schein, Inc.	$ 79	$ 131	$ 350	$ 454

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 26, 2020	$ 3,984	$ 1	$ 0	$ 3,455	$ (108)	$ 636
Beginning Balance, shares (in shares) at Dec. 26, 2020		142,462,571
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	489	$ 0	0	484	0	5
Foreign currency translation loss (excluding loss amounts attributable to Redeemable noncontrolling interests)	(36)	0	0	0	(36)	0
Unrealized gain from foreign currency hedging activities, net of tax	5	0	0	0	5	0
Pension adjustment gain, net of tax	1	0	0	0	1	0
Change in fair value of redeemable securities	(144)	0	(144)	0	0	0
Redeemable noncontrolling interests	7	0	0	0	0	7
Repurchases and retirement of common stock - Value	(251)	$ 0	(34)	(217)	0	0
Repurchases and retirement of common stock - Shares		(3,518,846)
Stock-based compensation expense - Value	58	$ 0	58	0	0	0
Stock-based compensation expense - Shares		299,572
Shares withheld for payroll taxes - Value	(7)	$ 0	(7)	0	0	0
Shares withheld for payroll taxes - Shares		(113,754)
Transfer of charges in excess of capital	0	$ 0	127	(127)	0	0
Ending Balance at Sep. 25, 2021	4,106	$ 1	0	3,595	(138)	648
Ending Balance, shares (in shares) at Sep. 25, 2021		139,129,543
Beginning Balance at Jun. 26, 2021	4,006	$ 1	0	3,466	(107)	646
Beginning Balance, shares (in shares) at Jun. 26, 2021		139,780,841
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	164	$ 0	0	162	0	2
Foreign currency translation loss (excluding loss amounts attributable to Redeemable noncontrolling interests)	(35)	0	0	0	(35)	0
Unrealized gain from foreign currency hedging activities, net of tax	4	0	0	0	4	0
Pension adjustment gain, net of tax	0
Change in fair value of redeemable securities	(11)	0	(11)	0	0	0
Repurchases and retirement of common stock - Value	(50)	$ 0	(7)	(43)	0	0
Repurchases and retirement of common stock - Shares		(651,289)
Stock-based compensation expense - Value	28	$ 0	28	0	0	0
Stock-based compensation expense - Shares		11
Shares withheld for payroll taxes - Value	0	$ 0	0	0	0	0
Shares withheld for payroll taxes - Shares		(20)
Transfer of charges in excess of capital	0	$ 0	(10)	10	0	0
Ending Balance at Sep. 25, 2021	4,106	$ 1	0	3,595	(138)	648
Ending Balance, shares (in shares) at Sep. 25, 2021		139,129,543
Beginning Balance at Dec. 25, 2021	$ 4,063	$ 1	0	3,595	(171)	638
Beginning Balance, shares (in shares) at Dec. 25, 2021	137,145,558	137,145,558
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	$ 496	$ 0	0	491	0	5
Foreign currency translation loss (excluding loss amounts attributable to Redeemable noncontrolling interests)	(163)	0	0	0	(162)	(1)
Unrealized gain from foreign currency hedging activities, net of tax	20	0	0	0	20	0
Pension adjustment gain, net of tax	1	0	0	0	1	0
Dividends paid	(1)	0	0	0	0	(1)
Purchase of noncontrolling interests	(7)	0	0	0	0	(7)
Change in fair value of redeemable securities	18	0	18	0	0	0
Repurchases and retirement of common stock - Value	(200)	$ 0	(28)	(172)	0	0
Repurchases and retirement of common stock - Shares		(2,529,126)
Stock-based compensation expense - Value	44	$ 0	44	0	0	0
Stock-based compensation expense - Shares		958,539
Stock issued upon exercise of stock options - Value	$ 2	$ 0	2	0	0	0
Stock issued upon exercise of stock options - Shares	30,554	30,424
Shares withheld for payroll taxes - Value	$ (30)	$ 0	(30)	0	0	0
Shares withheld for payroll taxes - Shares		(343,541)
Settlement of stock-based compensation awards - Value	2	$ 0	2	0	0	0
Settlement of stock-based compensation awards - Shares		(2,967)
Transfer of charges in excess of capital	0	$ 0	(8)	8	0	0
Ending Balance at Sep. 24, 2022	$ 4,245	$ 1	0	3,922	(312)	634
Ending Balance, shares (in shares) at Sep. 24, 2022	135,258,887	135,258,887
Beginning Balance at Jun. 25, 2022	$ 4,227	$ 1	0	3,834	(241)	633
Beginning Balance, shares (in shares) at Jun. 25, 2022		136,439,560
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	152	$ 0	0	150	0	2
Foreign currency translation loss (excluding loss amounts attributable to Redeemable noncontrolling interests)	(83)	0	0	0	(83)	0
Unrealized gain from foreign currency hedging activities, net of tax	11	0	0	0	11	0
Pension adjustment gain, net of tax	1	0	0	0	1	0
Dividends paid	(1)	0	0	0	0	(1)
Change in fair value of redeemable securities	11	0	11	0	0	0
Repurchases and retirement of common stock - Value	(90)	$ 0	(12)	(78)	0	0
Repurchases and retirement of common stock - Shares		(1,183,729)
Stock-based compensation expense - Value	17	$ 0	17	0	0	0
Stock-based compensation expense - Shares		3,640
Stock issued upon exercise of stock options - Value	0	$ 0	0	0	0	0
Stock issued upon exercise of stock options - Shares		597
Shares withheld for payroll taxes - Value	(1)	$ 0	(1)	0	0	0
Shares withheld for payroll taxes - Shares		(1,194)
Settlement of stock-based compensation awards - Value	1	$ 0	1	0	0	0
Settlement of stock-based compensation awards - Shares		13
Transfer of charges in excess of capital	0	$ 0	(16)	16	0	0
Ending Balance at Sep. 24, 2022	$ 4,245	$ 1	$ 0	$ 3,922	$ (312)	$ 634
Ending Balance, shares (in shares) at Sep. 24, 2022	135,258,887	135,258,887

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Net income attributable to Redeemable noncontrolling interests	$ 10	$ 5	$ 19	$ 19	$ 23
Foreign currency translation gain (loss) attributable to Redeemable noncontrolling interests	(6)	(5)	(13)	(4)	$ (6)
Unrealized gain from foreign currency hedging activities, tax	4	1	7	2
Pension adjustment gain, tax	$ (1)	$ 0	$ (1)	$ 0

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021
Cash flows from operating activities:
Net income	$ 515	$ 508
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	160	151
Gain on sale of equity investment	0	(10)
Stock-based compensation expense	44	58
Provision for (benefit from) losses on trade and other accounts receivable	2	(9)
Benefit from deferred income taxes	(20)	(1)
Equity in earnings of affiliates	(12)	(18)
Distributions from equity affiliates	12	15
Changes in unrecognized tax benefits	1	(6)
Other	(25)	0
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(93)	(83)
Inventories	(9)	(208)
Other current assets	(96)	(41)
Accounts payable and accrued expenses	(131)	77
Net cash provided by operating activities	348	433
Cash flows from investing activities:
Purchases of fixed assets	(67)	(49)
Payments related to equity investments and business acquisitions, net of cash acquired	(127)	(415)
Proceeds from sale of equity investments	0	10
Proceeds from (payments for) loan to affiliate	9	(6)
Other	(26)	(19)
Net cash used in investing activities	(211)	(479)
Cash flows from financing activities:
Net change in bank borrowings	51	(13)
Proceeds from issuance of long-term debt	165	200
Principal payments for long-term debt	(58)	(122)
Debt issuance costs	0	(2)
Proceeds from issuance of stock upon exercise of stock options	2	0
Payments for repurchases and retirement of common stock	(200)	(251)
Payments for taxes related to shares withheld for employee taxes	(30)	(7)
Distributions to noncontrolling shareholders	(18)	(9)
Acquisitions of noncontrolling interests in subsidiaries	(33)	(50)
Net cash used in financing activities	(121)	(254)
Effect of exchange rate changes on cash and cash equivalents	(11)	(2)
Net change in cash and cash equivalents	5	(302)
Cash and cash equivalents, beginning of period	118	421
Cash and cash equivalents, end of period	$ 123	$ 119

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 24, 2022
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries (“we”, “us” or “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 25, 2021 and with the information contained in our other publicly- available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the nine months ended September 24, 2022 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 31, 2022. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At September 24, 2022 and December 25, 2021, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 313 million and $ 138 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 225 million and $ 105 million, respectively. Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. Due to the significant uncertainty surrounding the future impact of COVID-19, our judgments regarding estimates and impairments could change in the future. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and may result in a material adverse effect on our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at this time

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	9 Months Ended
	Sep. 24, 2022
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards [Abstract]
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards Critical Accounting Policies There have been no material changes in our critical accounting policies during the nine months ended September 24, 2022, as compared to the critical accounting policies described in Item 7 of our Annual Report on Form 10-K for the year ended December 25, 2021. Accounting Pronouncements Adopted On December 26, 2021 we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Subtopic 805). ASU 2021 – 08 requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. Our adoption of ASU 2021 - 08 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”). ASU 2021-01 provides temporary optional expedients and exceptions to certain guidance in U.S. GAAP to ease the financial reporting burdens related to the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate. The guidance is effective upon issuance, on January 7, 2021, and can be applied through December 31, 2022. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements. In March 2022, the FASB issued ASU No. 2022-01, “Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method,” which will expand companies' abilities to hedge the benchmark interest rate risk of portfolios of financial assets (or beneficial interests) in a fair value hedge. This ASU expands the use of the portfolio layer method (previously referred to as the last-of-layer method) to allow multiple hedges of a single closed portfolio of assets using spot starting, forward starting and amortizing-notional swaps. It also permits both prepayable and non-prepayable financial assets to be included in the closed portfolio of assets hedged in a portfolio layer hedge. This ASU further requires that basis adjustments not be allocated to individual assets for active portfolio layer method hedges, but rather be maintained on the closed portfolio of assets as a whole. ASU 2022 – 01 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted for any entity that has adopted the amendments in ASU 2017-12. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

Revenue from Contracts with Customers	9 Months Ended
Revenue from Contracts with Customers	Sep. 24, 2022
Revenue from Contracts with Customers [Abstract]
Revenue from Contracts with Customers	Note 3 – Revenue from Contracts with Customers Revenue is recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 25, 2021. Disaggregation of Net Sales The following table disaggregates our Net sales by reportable segment and geographic area: Three Months Ended Nine Months Ended September 24, 2022 September 24, 2022 North America International Global North America International Global Net Sales: Health care distribution Dental $ 1,131 $ 654 $ 1,785 $ 3,360 $ 2,106 $ 5,466 Medical 1,088 18 1,106 3,215 59 3,274 Total health care distribution 2,219 672 2,891 6,575 2,165 8,740 Technology and value-added services 155 21 176 469 67 536 Total revenues $ 2,374 $ 693 $ 3,067 $ 7,044 $ 2,232 $ 9,276 Three Months Ended Nine Months Ended September 25, 2021 September 25, 2021 North America International Global North America International Global Net Sales: Health care distribution Dental $ 1,115 $ 708 $ 1,823 $ 3,289 $ 2,235 $ 5,524 Medical 1,162 23 1,185 3,000 78 3,078 Total health care distribution 2,277 731 3,008 6,289 2,313 8,602 Technology and value-added services 149 21 170 404 64 468 Total revenues $ 2,426 $ 752 $ 3,178 $ 6,693 $ 2,377 $ 9,070 At December 25, 2021, the current portion of contract liabilities of $ 89 million was reported in Accrued expenses: Other, and $ 10 million related to non-current contract liabilities was reported in Other liabilities. During the nine months ended September 24, 2022, we recognized in net sales $ 70 million of the amounts that were previously deferred at December 25, 2021. At September 24, 2022, the current and non-current portion of contract liabilities were $ 76 million and $ 9 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Segment Data	9 Months Ended
Segment Data	Sep. 24, 2022
Segment Data [Abstract]
Segment Data	Note 4 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools and other institutions. Our global medical businesses serve office-based medical practitioners, ambulatory surgery centers, other alternate-care settings and other institutions. Our global dental and medical groups serve practitioners in 32 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) and vitamins. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Net Sales: Health care distribution Dental $ 1,785 $ 1,823 $ 5,466 $ 5,524 Medical 1,106 1,185 3,274 3,078 Total health care distribution 2,891 3,008 8,740 8,602 Technology and value-added services 176 170 536 468 Total $ 3,067 $ 3,178 $ 9,276 $ 9,070 Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Operating Income: Health care distribution $ 179 $ 179 $ 579 $ 558 Technology and value-added services 32 32 96 93 Total $ 211 $ 211 $ 675 $ 651

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Business Acquisitions	9 Months Ended
Business Acquisitions	Sep. 24, 2022
Business Acquisitions [Abstract]
Business Acquisitions	Note 5 – Business Acquisitions 2022 Acquisitions We completed several acquisitions during the nine months ended September 24, 2022, which were immaterial to our condensed consolidated financial statements. Our acquired ownership interest ranged between 80 % to 100 %. Acquisitions within our healthcare distribution segment included companies that specialize in the distribution of dental products. Within our technology and value-added services segment, we acquired a company that educates and connects dental office managers, practice administrators and dental business leaders across North America. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the nine months ended September 24, 2022. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our condensed consolidated balance sheets. Approximately half of the acquired goodwill is deductible for tax purposes. 2022 Acquisition consideration: Cash $ 132 Deferred consideration 1 Fair value of previously held equity method investment 16 Redeemable noncontrolling interests 4 Total consideration $ 153 Identifiable assets acquired and liabilities assumed: Current assets 36 Intangible assets 70 Other noncurrent assets 7 Current liabilities (23) Deferred income taxes (5) Other noncurrent liabilities (5) Total identifiable net assets 80 Goodwill 73 Total net assets acquired $ 153 The following table summarizes the identifiable intangible assets acquired during the nine months ended September 24, 2022 and their estimated useful lives as of the date of the acquisition: 2022 Estimated Useful Lives (in years) Customer relationships and lists $ 56 10 Trademarks/ Tradenames 10 5 Non-compete agreements 2 2 - 5 Other 2 10 Total $ 70 2021 Acquisitions We completed several acquisitions during the nine months ended September 25, 2021 which were immaterial to our financial statements. Our acquired ownership interest ranged between approximately 51 % to 100 %. Acquisitions within our health care distribution segment included companies that specialize in the distribution and manufacturing of dental and medical products, a provider of home medical supplies, and product kitting and sterile packaging. Within our technology and value-added services segment, we acquired companies that focus on dental marketing and website solutions, practice transition services, and business analytics and intelligence software. The following table aggregates the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the nine months ended September 25, 2021. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our condensed consolidated balance sheets. 2021 Acquisition consideration: Cash $ 424 Deferred consideration 11 Fair value of previously held equity method investment 8 Redeemable noncontrolling interests 179 Total consideration $ 622 Identifiable assets acquired and liabilities assumed: Current assets 159 Intangible assets 259 Other noncurrent assets 39 Current liabilities (62) Deferred income taxes (18) Other noncurrent liabilities (39) Total identifiable net assets 338 Goodwill 284 Total net assets acquired $ 622 The following table summarizes the identifiable intangible assets acquired during the nine months ended September 25, 2021 and their estimated useful lives as of the date of the acquisition: 2021 Estimated Useful Lives (in years) Customer relationships and lists $ 175 6 - 12 Trademarks / Tradenames 42 5 - 10 Non-compete agreements 6 5 Product development 21 5 - 10 Other 15 18 Total $ 259 The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development and non-compete agreements), inventory and accounts receivable, property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from analysis of market conditions, discount rates, discounted cash flows, customer retention rates and estimated useful lives. Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our condensed consolidated statements of income. For the nine months ended September 24, 2022 and September 25, 2021, there were no material adjustments recorded in our condensed consolidated statements of income relating to changes in estimated contingent purchase price liabilities. During the nine months ended September 24, 2022 and September 25, 2021 we incurred $ 6 million and $ 6 million, respectively, in acquisition costs.

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 24, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 6 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy, and as of September 24, 2022 and December 25, 2021 was estimated at $ 1,045 million and $ 873 million, respectively. Factors that we considered when estimating the fair value of our debt included market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental executive retirement plan and our deferred compensation plan. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. See for additional information. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 24, 2022 and December 25, 2021: September 24, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 40 $ - $ 40 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 44 $ - $ 44 Liabilities: Derivative contracts designated as hedges $ - $ 3 $ - $ 3 Derivative contracts undesignated - 7 - 7 Total return swaps - 7 - 7 Total liabilities $ - $ 17 $ - $ 17 Redeemable noncontrolling interests $ - $ - $ 563 $ 563 December 25, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swaps - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 613 $ 613

Debt	9 Months Ended
Debt	Sep. 24, 2022
Debt [Abstract]
Debt	Note 7 – Debt Bank Credit Lines Bank credit lines consisted of the following: September 24, December 25, 2022 2021 Revolving credit agreement $ - $ - Other short-term bank credit lines 107 51 Total $ 107 $ 51 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1 billion revolving credit agreement (the “Credit Agreement”). This facility which matures on August 20, 2026 replaced our $ 750 million revolving credit facility which was scheduled to mature in April 2022. The interest rate is based on the USD LIBOR plus a spread based on our leverage ratio at the end of each financial reporting quarter. Most LIBOR rates have been discontinued after December 31, 2021, while the remaining LIBOR rates will be discontinued immediately after June 30, 2023. We do not expect the discontinuation of LIBOR as a reference rate in our debt agreements to have a material adverse effect on our financial position or to materially affect our interest expense. The Credit Agreement also requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 24, 2022 and December 25, 2021, we had no borrowings under this revolving credit facility. As of September 24, 2022 and December 25, 2021, there were $ 9 million and $ 9 million of letters of credit, respectively, provided to third parties under the credit facility. Other Short-Term Bank Credit Lines As of September 24, 2022 and December 25, 2021, we had various other short-term bank credit lines available, of which $ 107 million and $ 51 million, respectively, were outstanding. At September 24, 2022 and December 25, 2021, borrowings under all of these credit lines had a weighted average interest rate of 9.35 % and 10.44 %, respectively. Long-term debt Long-term debt consisted of the following: September 24, December 25, 2022 2021 Private placement facilities $ 699 $ 706 U.S. trade accounts receivable securitization 225 105 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.50 % at September 24, 2022 and ranging from 2.62 % to 4.27 % at December 25, 2021 7 4 Finance lease obligations 7 7 Total 938 822 Less current maturities (4) (11) Total long-term debt $ 934 $ 811 Private Placement Facilities Our private placement facilities were amended on October 20, 2021 to include four (previously three ) insurance companies, have a total facility amount of $ 1.5 billion (previously $ 1.0 billion), and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 (previously June 23, 2023 ). The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings as of September 24, 2022 are presented in the following table: Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699 U.S. Trade Accounts Receivable Securitization We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . On October 20, 2021, we extended the expiration date of this facility agreement to October 18, 2024 and increased the purchase limit under the facility from $ 350 million to $ 450 million with two banks as agents. As of September 24, 2022 and December 25, 2021, the borrowings outstanding under this securitization facility were $ 225 million and $ 105 million, respectively. At September 24, 2022, the interest rate on borrowings under this facility was based on the asset- backed commercial paper rate of 2.89 % plus 0.75 %, for a combined rate of 3.64 %. At December 25, 2021, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.19 % plus 0.75 %, for a combined rate of 0.94 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 24, 2022
Income Taxes [Abstract]
Income Taxes	Note 8 – Income Taxes For the nine months ended September 24, 2022 our effective tax rate was 23.5 % compared to 24.2 % for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 24, 2022 primarily relates to state and foreign income taxes and interest expense as well as share- based compensation. The difference between our effective tax rate and the federal statutory tax rate for the nine months ended September 25, 2021 primarily relates to state and foreign income taxes, interest expense and tax charges and credits associated with legal entity reorganizations. On August 16, 2022, the Inflation Reduction Act (H.R. 5376) (“IRA”) was signed into law in the United States. Among other things, the IRA imposes a 15% corporate alternative minimum tax for tax years beginning after December 31, 2022 and levies a 1% excise tax on net stock repurchases after December 31, 2022. We are still in the process of analyzing the provisions of the IRA. The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our condensed consolidated balance sheets, as of September 24, 2022 and December 25, 2021 was $ 84 million and $ 84 million, respectively, of which $ 71 million and $ 69 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2016. The tax years subject to examination by the IRS include years 2017 and forward. During the year ended December 25, 2021, we were notified by the IRS that tax year 2019 was selected for examination. During the quarter ended September 26, 2020 we reached an agreement with the Advanced Pricing Division on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution was to mitigate future transfer pricing audit adjustments. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense/(credit) was $ 1 million for the nine months ended September 24, 2022, and $ (2) million for the nine months ended September 25, 2021. The total amount of accrued interest is included in “Other liabilities,” and was $ 14 million as of September 24, 2022 and $ 12 million as of December 25, 2021. No penalties were accrued for the periods presented.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Legal Proceedings	9 Months Ended
Legal Proceedings	Sep. 24, 2022
Legal Proceedings [Abstract]
Legal Proceedings	Note 9 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty ( 150 ); in less than half of those cases one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its affiliated companies) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by Mobile County Board of Health, et al., in Alabama state court, which is currently stayed but remains set for a jury trial on January 9, 2023; the action filed by DCH Health Care Authority, et al. in Alabama state court, which has been designated a bellwether with eight of thirty-eight plaintiffs set for a jury trial on July 24, 2023; and the action filed by Florida Health Sciences Center, Inc. (and 38 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in October 2024. In June 2022, we settled twenty-six cases filed by hospitals in West Virginia, and settled with one additional hospital, for a total amount of three-hundred thousand dollars. The twenty-six cases have been dismissed. Of Henry Schein’s 2021 net sales of approximately $ 12.4 billion, sales of opioids represented less than two-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of September 24, 2022, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 24, 2022
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 10 – Stock-Based Compensation Stock-based awards are provided to certain employees under the terms of our 2020 Stock Incentive Plan and to non-employee directors under the terms of our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”). However, for our 2021 fiscal year, in light of the COVID-19 pandemic, the Compensation Committee determined it would be difficult for management to set a meaningful three-year cumulative earnings per share target as the goal applicable to performance-based RSU awards as it had done in prior years. Instead, the Compensation Committee set our equity-based awards to employees for fiscal 2021 in the form of time-based RSUs and non-qualified stock options which focus on stock value appreciation and retention instead of pre-established performance goals. Our non-employee directors continued to receive equity-based awards for fiscal 2021 solely in the form of time-based RSUs. In March 2022, the Compensation Committee reinstated performance-based RSUs for equity-based awards to employees for fiscal 2022 and awarded grants in the form of time-based RSUs, performance-based RSUs and non-qualified stock options. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted under the 2015 Non-Employee Director Stock Incentive Plan primarily are granted with 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at the time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact, either positive or negative, of the differences in projected earnings generated by sales of COVID- 19 test kits (solely with respect to performance-based RSUs granted in the 2022 plan year) and unforeseen events or circumstances affecting us. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued beginning in 2021 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimate the fair value of stock options using the Black-Scholes valuation model. In addition to equity-based awards granted in fiscal 2021 under the long-term incentive program, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. The payout under the performance-based restricted stock units granted under the fiscal 2018 long-term incentive program (the “2018 LTIP”) was negatively impacted by the global COVID-19 pandemic. Given the significance of the impact of the pandemic on our three - year EPS goal under such equity awards and the contributions made by our employees (including those who received such awards), on March 3, 2021, the Compensation Committee granted a Special Pandemic Recognition Award to recipients of performance-based restricted stock units under the 2018 LTIP who were employed by us on the grant date of the Special Pandemic Recognition Award. These time-based RSU awards vest 50 % on the first anniversary of the grant date and 50 % on the second anniversary of the grant date, based on the recipient’s continued service and subject to the terms and conditions of the 2020 Stock Incentive Plan, and are recorded as compensation expense using a graded vesting method. The combination of the 20 % payout based on actual performance of the 2018 LTIP and the one-time Special Pandemic Recognition Award granted in 2021 will generate a cumulative payout of 75 % of each recipient’s original number of performance-based restricted stock units awarded in 2018 if the recipient satisfies the two -year vesting schedule commencing on the grant date. Our accompanying condensed consolidated statements of income reflect pre-tax share-based compensation expense of $ 17 million ($ 13 million after-tax) and $ 44 million ($ 34 million after-tax) for the three and nine months ended September 24, 2022, respectively. For the three and nine months ended September 25, 2021, we recorded pre-tax share-based compensation expense of $ 28 million ($ 21 million after-tax) and $ 58 million ($ 44 million after-tax), respectively. Total unrecognized compensation cost related to unvested awards as of September 24, 2022 was $ 104 million, which is expected to be recognized over a weighted-average period of approximately 2.2 years. The following weighted-average assumptions were used in determining the most recent fair values of stock options granted using the Black-Scholes valuation model: 2022 Expected dividend yield 0.0 % Expected stock price volatility 27.70 % Risk-free interest rate 3.42 % Expected life of options (years) 6.00 We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The six -year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us. The following table summarizes stock option activity under the Plans during the nine months ended September 24, 2022: Stock Options Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Life in Intrinsic Shares Price Years Value Outstanding at beginning of period 767,717 $ 63.24 Granted 418,425 85.82 Exercised (30,554) 62.71 Forfeited (17,850) 72.96 Outstanding at end of period 1,137,738 $ 71.41 8.8 $ 3 Options exercisable at end of period 223,198 $ 63.19 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 898,310 $ 73.60 8.9 $ 2 The following tables summarize the activity of our unvested RSUs for the nine months ended September 24, 2022: Time-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,945,862 $ 58.79 Granted 466,473 85.67 Vested (505,004) 54.74 Forfeited (54,618) 67.23 Outstanding at end of period 1,852,713 $ 66.39 $ 67.34 Performance-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 674,753 $ 59.63 Granted 442,871 76.68 Vested (392,646) 59.18 Forfeited (13,631) 67.17 Outstanding at end of period 711,347 $ 63.27 $ 67.34

Redeemable Noncontrolling Interests	9 Months Ended
Redeemable Noncontrolling Interests	Sep. 24, 2022
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 11 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the nine months ended September 24, 2022 and the year ended December 25, 2021 are presented in the following table: September 24, December 25, 2022 2021 Balance, beginning of period $ 613 $ 328 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (26) (60) Increase in redeemable noncontrolling interests due to business acquisitions 4 189 Net income attributable to redeemable noncontrolling interests 19 23 Dividends declared (16) (21) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (13) (6) Change in fair value of redeemable securities (18) 160 Balance, end of period $ 563 $ 613

Comprehensive Income	9 Months Ended
Comprehensive Income	Sep. 24, 2022
Comprehensive Income [Abstract]
Comprehensive Income	Note 12 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: September 24, December 25, 2022 2021 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (44) $ (31) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ - Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (317) $ (155) Unrealized gain (loss) from foreign currency hedging activities 18 (2) Pension adjustment loss (13) (14) Accumulated other comprehensive loss $ (312) $ (171) Total Accumulated other comprehensive loss $ (357) $ (202) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Net income $ 162 $ 169 $ 515 $ 508 Foreign currency translation loss (89) (40) (176) (40) Tax effect - - - - Foreign currency translation loss (89) (40) (176) (40) Unrealized gain from foreign currency hedging activities 15 5 27 7 Tax effect (4) (1) (7) (2) Unrealized gain from foreign currency hedging activities 11 4 20 5 Pension adjustment gain 2 - 2 1 Tax effect (1) - (1) - Pension adjustment gain 1 - 1 1 Comprehensive income $ 85 $ 133 $ 360 $ 474 The change in the unrealized gain from foreign currency hedging activities during the three and nine months ended September 24, 2022 and September 25, 2021 was primarily attributable to a net investment hedge that was entered into during 2019. Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation loss during the nine months ended September 24, 2022 was primarily due to strengthening of the U.S. Dollar as compared to the Euro, British Pound, Australian Dollar and Canadian Dollar. The following table summarizes our total comprehensive income, net of applicable taxes, as follows: Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Comprehensive income attributable to Henry Schein, Inc. $ 79 $ 131 $ 350 $ 454 Comprehensive income attributable to noncontrolling interests 2 2 4 5 Comprehensive income attributable to Redeemable noncontrolling interests 4 - 6 15 Comprehensive income $ 85 $ 133 $ 360 $ 474

Plans of Restructuring and Integration Costs	9 Months Ended
Plans of Restructuring and Integration Costs	Sep. 24, 2022
Plans of Restructuring and Integration Costs [Abstract]
Plans of Restructuring and Integration Costs	Note 13 – Plans of Restructuring On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and streamlining operations and other initiatives to increase efficiency. This plan also includes the rationalization of the Company’s office space in North America as a result of transitioning to a partial and full remote work model for certain employees. We recorded restructuring charges of $ 9 million primarily related to severance and employee- related costs and lease right-of-use and other long-lived asset accelerated depreciation and amortization and lease exit costs. We expect this initiative to extend through 2023. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the three months ended September 24, 2022, we recorded integration costs of $ 1 million related to one-time employee and other costs, as well as restructuring charges of $ 2 million, which are included in the $ 9 million of restructuring charges discussed above. On November 20, 2019, we committed to a contemplated restructuring initiative intended to mitigate stranded costs associated with the spin-off of our animal health business and to rationalize operations and provide expense efficiencies. These activities were originally expected to be completed by the end of 2020 but we extended them to the end of 2021 in light of the changes to the business environment brought on by the COVID-19 pandemic. The restructuring activities under this prior initiative were completed in 2021. Restructuring and integration costs recorded for the three and nine months ended September 24, 2022 and nine months ended September 25, 2021 (there were no restructuring costs for the three months ended September 25, 2021) consisted of the following: Three and Nine Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 6 $ - $ - $ - $ 6 Accelerated depreciation and amortization 2 - - - 2 Exit and other related costs 1 - - - 1 Integration employee-related and other costs - 1 - - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ - $ 10 Nine Months Ended September 25, 2021 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 3 $ - $ 1 $ - $ 4 Total restructuring and integration costs $ 3 $ - $ 1 $ - $ 4 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the period ended September 24, 2022. The remaining accrued balance of restructuring costs as of September 24, 2022 is included in accrued expenses: other within our condensed consolidated balance sheet. Technology and Health Care Value-Added Distribution Services Total Balance, December 25, 2021 $ 3 $ 1 $ 4 Restructuring charges 9 - 9 Non-cash charges (2) - (2) Cash payments and other adjustments (5) (1) (6) Balance, September 24, 2022 $ 5 $ - $ 5

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 24, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Note 14 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Basic 135,608,678 139,377,237 136,731,413 140,661,182 Effect of dilutive securities: Stock options and restricted stock units 1,475,371 1,702,100 1,756,841 1,517,520 Diluted 137,084,049 141,079,337 138,488,254 142,178,702 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Stock options 482,497 789,130 310,565 595,798 Restricted stock units 445,494 - 261,718 5,716 Total anti-dilutive securities excluded from EPS computation 927,991 789,130 572,283 601,514

Supplemental Cash Flow Information	9 Months Ended
Supplemental Cash Flow Information	Sep. 24, 2022
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 15 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Nine Months Ended September 24, September 25, 2022 2021 Interest $ 29 $ 22 Income taxes 235 179 During the nine months ended September 24, 2022 and September 25, 2021, we had $ 27 million and $ 7 million, respectively of non-cash net unrealized gains related to foreign currency hedging activities.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 24, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 16 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the three and nine months ended September 24, 2022, we recorded $ 8 million and $ 23 million, respectively in connection with costs related to this royalty agreement. During the three and nine months ended September 25, 2021, we recorded $ 8 million and $ 23 million, respectively, in connection with costs related to this royalty agreement. As of September 24, 2022 and December 25, 2021, Henry Schein One, LLC had a net (payable) receivable balance due (to) from Internet Brands of $ (14) million and $ 9 million, respectively, comprised of amounts related to results of operations and the royalty agreement. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three and nine months ended September 24, 2022, we recorded net sales of $ 16 million and $ 49 million, respectively, to such entities. During the three and nine months ended September 25, 2021, we recorded net sales of $ 18 million and $ 51 million, respectively, to such entities. During the three and nine months ended September 24, 2022, we purchased $ 4 million and $ 14 million, respectively, from such entities. During the three and nine months ended September 25, 2021, we purchased $ 5 million and $ 14 million, respectively, from such entities. At September 24, 2022 and December 25, 2021, in the aggregate we had $ 39 million and $ 45 million due from our equity affiliates, and $ 9 million and $ 9 million due to our equity affiliates, respectively. Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from one year to 9 years . As of September 24, 2022, current and non-current liabilities associated with related party operating leases were $ 4 million and $ 16 million, respectively. Related party leases represented 5.2 % and 5.8 % of the total current and non- current operating lease liabilities.

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards (Policy)	9 Months Ended
	Sep. 24, 2022
Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards [Abstract]
Accounting Pronouncements Adopted and Recently Issued Accounting Standards	Accounting Pronouncements Adopted On December 26, 2021 we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Subtopic 805). ASU 2021 – 08 requires an acquirer to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree’s financial statements. Our adoption of ASU 2021 - 08 did not have a material impact on our consolidated financial statements. Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope (“ASU 2021-01”). ASU 2021-01 provides temporary optional expedients and exceptions to certain guidance in U.S. GAAP to ease the financial reporting burdens related to the expected market transition from LIBOR and other interbank offered rates to alternative reference rates, such as the Secured Overnight Financing Rate. The guidance is effective upon issuance, on January 7, 2021, and can be applied through December 31, 2022. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements. In March 2022, the FASB issued ASU No. 2022-01, “Derivatives and Hedging (Topic 815): Fair Value Hedging – Portfolio Layer Method,” which will expand companies' abilities to hedge the benchmark interest rate risk of portfolios of financial assets (or beneficial interests) in a fair value hedge. This ASU expands the use of the portfolio layer method (previously referred to as the last-of-layer method) to allow multiple hedges of a single closed portfolio of assets using spot starting, forward starting and amortizing-notional swaps. It also permits both prepayable and non-prepayable financial assets to be included in the closed portfolio of assets hedged in a portfolio layer hedge. This ASU further requires that basis adjustments not be allocated to individual assets for active portfolio layer method hedges, but rather be maintained on the closed portfolio of assets as a whole. ASU 2022 – 01 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted for any entity that has adopted the amendments in ASU 2017-12. We do not expect that the requirements of this guidance will have a material impact on our consolidated financial statements.

Revenue from Contracts with Customers (Tables)	9 Months Ended
Revenue from Contracts with Customers (Tables)	Sep. 24, 2022
Revenue from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended Nine Months Ended September 24, 2022 September 24, 2022 North America International Global North America International Global Net Sales: Health care distribution Dental $ 1,131 $ 654 $ 1,785 $ 3,360 $ 2,106 $ 5,466 Medical 1,088 18 1,106 3,215 59 3,274 Total health care distribution 2,219 672 2,891 6,575 2,165 8,740 Technology and value-added services 155 21 176 469 67 536 Total revenues $ 2,374 $ 693 $ 3,067 $ 7,044 $ 2,232 $ 9,276 Three Months Ended Nine Months Ended September 25, 2021 September 25, 2021 North America International Global North America International Global Net Sales: Health care distribution Dental $ 1,115 $ 708 $ 1,823 $ 3,289 $ 2,235 $ 5,524 Medical 1,162 23 1,185 3,000 78 3,078 Total health care distribution 2,277 731 3,008 6,289 2,313 8,602 Technology and value-added services 149 21 170 404 64 468 Total revenues $ 2,426 $ 752 $ 3,178 $ 6,693 $ 2,377 $ 9,070

Segment Data (Tables)	9 Months Ended
Segment Data (Tables)	Sep. 24, 2022
Segment Data [Abstract]
Business segment information	Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Net Sales: Health care distribution Dental $ 1,785 $ 1,823 $ 5,466 $ 5,524 Medical 1,106 1,185 3,274 3,078 Total health care distribution 2,891 3,008 8,740 8,602 Technology and value-added services 176 170 536 468 Total $ 3,067 $ 3,178 $ 9,276 $ 9,070 Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Operating Income: Health care distribution $ 179 $ 179 $ 579 $ 558 Technology and value-added services 32 32 96 93 Total $ 211 $ 211 $ 675 $ 651

Business Acquisitions (Tables)	9 Months Ended
Business Acquisitions (Tables)	Sep. 24, 2022
Business Acquisitions [Abstract]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2022 Acquisition consideration: Cash $ 132 Deferred consideration 1 Fair value of previously held equity method investment 16 Redeemable noncontrolling interests 4 Total consideration $ 153 Identifiable assets acquired and liabilities assumed: Current assets 36 Intangible assets 70 Other noncurrent assets 7 Current liabilities (23) Deferred income taxes (5) Other noncurrent liabilities (5) Total identifiable net assets 80 Goodwill 73 Total net assets acquired $ 153 2021 Acquisition consideration: Cash $ 424 Deferred consideration 11 Fair value of previously held equity method investment 8 Redeemable noncontrolling interests 179 Total consideration $ 622 Identifiable assets acquired and liabilities assumed: Current assets 159 Intangible assets 259 Other noncurrent assets 39 Current liabilities (62) Deferred income taxes (18) Other noncurrent liabilities (39) Total identifiable net assets 338 Goodwill 284 Total net assets acquired $ 622
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2022 Estimated Useful Lives (in years) Customer relationships and lists $ 56 10 Trademarks/ Tradenames 10 5 Non-compete agreements 2 2 - 5 Other 2 10 Total $ 70 2021 Estimated Useful Lives (in years) Customer relationships and lists $ 175 6 - 12 Trademarks / Tradenames 42 5 - 10 Non-compete agreements 6 5 Product development 21 5 - 10 Other 15 18 Total $ 259

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 24, 2022
Fair Value Measurements [Abstract]
Fair value - assets and liabilities measured and recognized on a recurring basis	September 24, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 40 $ - $ 40 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 44 $ - $ 44 Liabilities: Derivative contracts designated as hedges $ - $ 3 $ - $ 3 Derivative contracts undesignated - 7 - 7 Total return swaps - 7 - 7 Total liabilities $ - $ 17 $ - $ 17 Redeemable noncontrolling interests $ - $ - $ 563 $ 563 December 25, 2021 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swaps - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 3 $ - $ 3 Redeemable noncontrolling interests $ - $ - $ 613 $ 613

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 24, 2022
Debt [Abstract]
Bank credit lines	September 24, December 25, 2022 2021 Revolving credit agreement $ - $ - Other short-term bank credit lines 107 51 Total $ 107 $ 51
Long-term debt	September 24, December 25, 2022 2021 Private placement facilities $ 699 $ 706 U.S. trade accounts receivable securitization 225 105 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 3.50 % at September 24, 2022 and ranging from 2.62 % to 4.27 % at December 25, 2021 7 4 Finance lease obligations 7 7 Total 938 822 Less current maturities (4) (11) Total long-term debt $ 934 $ 811
Private placement facilities	Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 Less: Deferred debt issuance costs (1) Total $ 699

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644

+ Details

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 24, 2022
Stock-Based Compensation [Abstract]
Assumptions used in Determining Fair Values of Stock Options using the Black-Scholes Valuation Model	2022 Expected dividend yield 0.0 % Expected stock price volatility 27.70 % Risk-free interest rate 3.42 % Expected life of options (years) 6.00
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Life in Intrinsic Shares Price Years Value Outstanding at beginning of period 767,717 $ 63.24 Granted 418,425 85.82 Exercised (30,554) 62.71 Forfeited (17,850) 72.96 Outstanding at end of period 1,137,738 $ 71.41 8.8 $ 3 Options exercisable at end of period 223,198 $ 63.19
Intrinsic Values	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 898,310 $ 73.60 8.9 $ 2
Status of Non-Vested Restricted Shares/Units	Time-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,945,862 $ 58.79 Granted 466,473 85.67 Vested (505,004) 54.74 Forfeited (54,618) 67.23 Outstanding at end of period 1,852,713 $ 66.39 $ 67.34 Performance-Based Restricted Stock Units Weighted Average Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Outstanding at beginning of period 674,753 $ 59.63 Granted 442,871 76.68 Vested (392,646) 59.18 Forfeited (13,631) 67.17 Outstanding at end of period 711,347 $ 63.27 $ 67.34

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
Redeemable Noncontrolling Interests (Tables)	Sep. 24, 2022
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	September 24, December 25, 2022 2021 Balance, beginning of period $ 613 $ 328 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (26) (60) Increase in redeemable noncontrolling interests due to business acquisitions 4 189 Net income attributable to redeemable noncontrolling interests 19 23 Dividends declared (16) (21) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (13) (6) Change in fair value of redeemable securities (18) 160 Balance, end of period $ 563 $ 613

Comprehensive Income (Tables)	9 Months Ended
Comprehensive Income (Tables)	Sep. 24, 2022
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	September 24, December 25, 2022 2021 Attributable to Redeemable noncontrolling interests: Foreign currency translation adjustment $ (44) $ (31) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ - Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (317) $ (155) Unrealized gain (loss) from foreign currency hedging activities 18 (2) Pension adjustment loss (13) (14) Accumulated other comprehensive loss $ (312) $ (171) Total Accumulated other comprehensive loss $ (357) $ (202)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Net income $ 162 $ 169 $ 515 $ 508 Foreign currency translation loss (89) (40) (176) (40) Tax effect - - - - Foreign currency translation loss (89) (40) (176) (40) Unrealized gain from foreign currency hedging activities 15 5 27 7 Tax effect (4) (1) (7) (2) Unrealized gain from foreign currency hedging activities 11 4 20 5 Pension adjustment gain 2 - 2 1 Tax effect (1) - (1) - Pension adjustment gain 1 - 1 1 Comprehensive income $ 85 $ 133 $ 360 $ 474
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Comprehensive income attributable to Henry Schein, Inc. $ 79 $ 131 $ 350 $ 454 Comprehensive income attributable to noncontrolling interests 2 2 4 5 Comprehensive income attributable to Redeemable noncontrolling interests 4 - 6 15 Comprehensive income $ 85 $ 133 $ 360 $ 474

Plans of Restructuring and Integration Costs (Tables)	9 Months Ended
Plans of Restructuring and Integration Costs (Tables)	Sep. 24, 2022
Plans of Restructuring and Integration Costs [Abstract]
Schedule of Restructuring Reserve by Type of Cost	Three and Nine Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 6 $ - $ - $ - $ 6 Accelerated depreciation and amortization 2 - - - 2 Exit and other related costs 1 - - - 1 Integration employee-related and other costs - 1 - - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ - $ 10 Nine Months Ended September 25, 2021 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Integration Costs Total Severance and employee-related costs $ 3 $ - $ 1 $ - $ 4 Total restructuring and integration costs $ 3 $ - $ 1 $ - $ 4
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 25, 2021 $ 3 $ 1 $ 4 Restructuring charges 9 - 9 Non-cash charges (2) - (2) Cash payments and other adjustments (5) (1) (6) Balance, September 24, 2022 $ 5 $ - $ 5

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Sep. 24, 2022
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Basic 135,608,678 139,377,237 136,731,413 140,661,182 Effect of dilutive securities: Stock options and restricted stock units 1,475,371 1,702,100 1,756,841 1,517,520 Diluted 137,084,049 141,079,337 138,488,254 142,178,702
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Nine Months Ended September 24, September 25, September 24, September 25, 2022 2021 2022 2021 Stock options 482,497 789,130 310,565 595,798 Restricted stock units 445,494 - 261,718 5,716 Total anti-dilutive securities excluded from EPS computation 927,991 789,130 572,283 601,514

Supplemental Cash Flow Information (Tables)	9 Months Ended
Supplemental Cash Flow Information (Tables)	Sep. 24, 2022
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Nine Months Ended September 24, September 25, 2022 2021 Interest $ 29 $ 22 Income taxes 235 179

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021
Asset Pledged as Collateral [Member]
Pledged assets	$ 313	$ 138
Recourse [Member]
Liabilities of VIE	$ 225	$ 105

Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting Standards - Narrative (Details) - Accounting Standards Update 2021-08 [Member]	Sep. 24, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Dec. 26, 2021

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232

+ Details

- Definition

Date accounting standards update was adopted, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

+ Details

Revenue from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 24, 2022	Dec. 25, 2021
Revenue from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 76	$ 89
Contract with Customer, Liability, Noncurrent	9	$ 10
Contract with Customer, Liability, Revenue Recognized	$ 70

Revenue from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Disaggregation of Revenue [Abstract]
Net sales	$ 3,067	$ 3,178	$ 9,276	$ 9,070
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,374	2,426	7,044	6,693
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	693	752	2,232	2,377
Health-Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,891	3,008	8,740	8,602
Health-Care Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,219	2,277	6,575	6,289
Health-Care Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	672	731	2,165	2,313
Health-Care Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,785	1,823	5,466	5,524
Health-Care Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,131	1,115	3,360	3,289
Health-Care Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	654	708	2,106	2,235
Health-Care Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,106	1,185	3,274	3,078
Health-Care Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,088	1,162	3,215	3,000
Health-Care Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	18	23	59	78
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	176	170	536	468
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	155	149	469	404
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 21	$ 21	$ 67	$ 64

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Data (Details) $ in Millions	3 Months Ended		9 Months Ended
Segment Data (Details) $ in Millions	Sep. 24, 2022 USD ($) countries	Sep. 25, 2021 USD ($)	Sep. 24, 2022 USD ($) segments countries	Sep. 25, 2021 USD ($)
Segment Data [Abstract]
Number of reportable segments \| segments			2
Segment Reporting Information [Line Items]
Net sales	$ 3,067	$ 3,178	$ 9,276	$ 9,070
Operating income	211	211	675	651
Health-Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,891	3,008	8,740	8,602
Operating income	$ 179	179	$ 579	558
Number of countries served globally \| countries	32		32
Health-Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,785	1,823	$ 5,466	5,524
Health-Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	1,106	1,185	3,274	3,078
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	176	170	536	468
Operating income	$ 32	$ 32	$ 96	$ 93

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions	Sep. 24, 2022	Sep. 25, 2021
Business Acquisition [Line Items]
Acquisition costs	$ 6	$ 6
Series Of Individually Immaterial Business Acquisitions [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	80.00%	51.00%
Series Of Individually Immaterial Business Acquisitions [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%	100.00%

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Acquisition consideration:
Redeemable noncontrolling interests		$ 7
Identifiable assets acquired and liabilities assumed:
Goodwill	$ 2,870		$ 2,854
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Cash	132	424
Deferred consideration	1	11
Fair value of previously held equity method investment	16	8
Redeemable noncontrolling interests	4	179
Total consideration	153	622
Identifiable assets acquired and liabilities assumed:
Current assets	36	159
Intangible assets	70	259
Other noncurrent assets	7	39
Current liabilities	(23)	(62)
Deferred income taxes	(5)	(18)
Other noncurrent liabilities	(5)	(39)
Total identifiable net assets	80	338
Goodwill	73	284
Total net assets acquired	$ 153	$ 622

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - Series Of Individually Immaterial Business Acquisitions [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired	$ 70	$ 259
Customer Relationships and Lists [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired	$ 56	175
Estimated Useful Lives (in years)	10 years
Trademarks/Tradenames [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired	$ 10	42
Estimated Useful Lives (in years)	5 years
Non-compete Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired	$ 2	$ 6
Estimated Useful Lives (in years)		5 years
Product Development [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired		$ 21
Other [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Identifiable Intangible Assets Acquired	$ 2	$ 15
Estimated Useful Lives (in years)	10 years	18 years
Minimum [Member] \| Customer Relationships and Lists [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		6 years
Minimum [Member] \| Trademarks/Tradenames [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		5 years
Minimum [Member] \| Non-compete Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)	2 years
Minimum [Member] \| Product Development [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		5 years
Maximum [Member] \| Customer Relationships and Lists [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		12 years
Maximum [Member] \| Trademarks/Tradenames [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		10 years
Maximum [Member] \| Non-compete Agreements [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)	5 years
Maximum [Member] \| Product Development [Member]
Acquired Finite Lived Intangible Assets [Line Items]
Estimated Useful Lives (in years)		10 years

Fair Value Measurements (Details) - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021	Dec. 26, 2020
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 563	$ 613	$ 328
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	44	10
Liabilities [Abstract]
Total liabilities	17	3
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	40	8
Liabilities [Abstract]
Derivative contracts - liabilities	3	1
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	4	1
Liabilities [Abstract]
Derivative contracts - liabilities	7	2
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps		1
Liabilities [Abstract]
Total return swaps	7
Fair value, measurements, recurring [Member]
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	563	613
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps		0
Liabilities [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	44	10
Liabilities [Abstract]
Total liabilities	17	3
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	40	8
Liabilities [Abstract]
Derivative contracts - liabilities	3	1
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	4	1
Liabilities [Abstract]
Derivative contracts - liabilities	7	2
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps		1
Liabilities [Abstract]
Total return swaps	7
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities		0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Assets [Abstract]
Total return swaps		0
Liabilities [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	563	613
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Estimate of Fair Value Measurement [Member]
Debt Instrument, Fair Value Disclosure [Abstract]
Fair value of debt (including bank credit lines)	$ 1,045	$ 873

Debt - Bank credit lines (Details) - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021
Line of Credit Facility [Line Items]
Bank Credit lines	$ 107	$ 51
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	0
Other Short Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 107	$ 51

Debt - Revolving Credit Agreement and Other Short-Term Credit Lines Narrative (Details) - USD ($)	9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021	Aug. 20, 2021	Aug. 19, 2021
Line of Credit Facility [Line Items]
Bank credit lines	$ 107,000,000		$ 51,000,000
Repayments of Long-term Debt	$ 58,000,000	$ 122,000,000
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Initiation Date	Aug. 20, 2021
Revolving credit facility borrowing capacity				$ 1,000,000,000	$ 750,000,000
Revolving credit facility expiration date	Aug. 20, 2026
Borrowings	$ 0		0
Outstanding letters of credit provided to third parties	9,000,000		9,000,000
Bank credit lines	0		0
Other Short Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank credit lines	$ 107,000,000		$ 51,000,000
Weighted average interest rate on borrowings under credit lines at period end (in hundredths)	9.35%		10.44%

Debt - Long-term Debt (Details) - USD ($) $ in Millions	Sep. 24, 2022	Dec. 25, 2021
Debt Instrument [Line Items]
Finance lease obligations	$ 7	$ 7
Total	938	822
Less current maturities	(4)	(11)
Long-term debt	934	811
Private placement facilities [Member]
Debt Instrument [Line Items]
Long-term debt	699	706
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Long-term debt	225	105
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 0% to 4.27% at March 26, 2022 and ranging from 2.62% to 4.27% at December 25, 2021 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 7	$ 4
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 0% to 4.27% at March 26, 2022 and ranging from 2.62% to 4.27% at December 25, 2021 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	0.00%	2.62%
Various collateralized and uncollateralized loans payable with interest in varying installments through 2023 at interest rates ranging from 0% to 4.27% at March 26, 2022 and ranging from 2.62% to 4.27% at December 25, 2021 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	3.50%	4.27%

Debt - Private Placement Facilities - Narrative (Details) - Private Placement Facilities [Member]		9 Months Ended
	Oct. 19, 2021 USD ($)	Sep. 24, 2022	Oct. 20, 2021 USD ($)
Debt Instrument [Line Items]
Date of borrowing		Oct. 20, 2021
Number of companies included in private placement facilities	3		4
Debt instrument maximum borrowing capacity	$ 1,000,000,000.0		$ 1,500,000,000
Debt instrument, maturity date	Jun. 23, 2023	Oct. 20, 2026
Average term of issuances under private placement facilities		12 years
Private placement facilities maturing in September 2030 [Member]
Debt Instrument [Line Items]
Date of borrowing		Sep. 02, 2020
Debt instrument, maturity date		Sep. 02, 2030
Private placement facilities maturing in June 2031 [Member]
Debt Instrument [Line Items]
Date of borrowing		Jun. 02, 2021
Debt instrument, maturity date		Jun. 02, 2031
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities		15 years

Debt - Private Placement Borrowings (Details) - Private placement facilities [Member] - USD ($) $ in Millions		9 Months Ended
	Oct. 19, 2021	Sep. 24, 2022	Dec. 25, 2021
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Oct. 20, 2021
Less: Deferred debt issuance costs		$ (1)
Total		$ 699	$ 706
Debt Instrument, Maturity Date	Jun. 23, 2023	Oct. 20, 2026
Private placement facilities maturing in January 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jan. 20, 2012
Long-term Debt, Gross		$ 50
Borrowing Rate		3.45%
Debt Instrument, Maturity Date		Jan. 20, 2024
Private placement facilities maturing in December 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Dec. 24, 2012
Long-term Debt, Gross		$ 50
Borrowing Rate		3.00%
Debt Instrument, Maturity Date		Dec. 24, 2024
Private Placement facilities maturing in June 2027 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 16, 2017
Long-term Debt, Gross		$ 100
Borrowing Rate		3.42%
Debt Instrument, Maturity Date		Jun. 16, 2027
Private Placement facilities maturing in September 2029 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 15, 2017
Long-term Debt, Gross		$ 100
Borrowing Rate		3.52%
Debt Instrument, Maturity Date		Sep. 15, 2029
Private Placement facilities maturing in January 2028 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jan. 02, 2018
Long-term Debt, Gross		$ 100
Borrowing Rate		3.32%
Debt Instrument, Maturity Date		Jan. 02, 2028
Private placement facilities maturing in September 2030 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Sep. 02, 2020
Long-term Debt, Gross		$ 100
Borrowing Rate		2.35%
Debt Instrument, Maturity Date		Sep. 02, 2030
Private placement facilities maturing in June 2031 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 02, 2021
Long-term Debt, Gross		$ 100
Borrowing Rate		2.48%
Debt Instrument, Maturity Date		Jun. 02, 2031
Private Placement Facilities maturing in June 2033 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date		Jun. 02, 2021
Long-term Debt, Gross		$ 100
Borrowing Rate		2.58%
Debt Instrument, Maturity Date		Jun. 02, 2033

Debt - U.S. Trade Accounts Receivable Securitization - Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member]	9 Months Ended	12 Months Ended
	Sep. 24, 2022 USD ($)	Dec. 25, 2021 USD ($)	Oct. 20, 2021 USD ($)	Oct. 19, 2021 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Oct. 18, 2024
Debt instrument maximum borrowing capacity			$ 450,000,000	$ 350,000,000
Long-term debt	$ 225,000,000	$ 105,000,000
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.35%
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.30%
Number of banks as agents for debt instrument			2
Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	3.64%	0.94%
Debt instrument, variable rate basis at period end	2.89%	0.19%
Debt instrument, basis spread on variable rate	0.75%	0.75%

Income Taxes - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
Income Taxes - Narrative (Details) - USD ($)	Sep. 24, 2022	Dec. 25, 2021	Sep. 25, 2021
Income Tax Examination [Line Items]
Effective tax rate	23.50%	24.20%
Unrecognized tax benefits	$ 84,000,000	$ 84,000,000
Unrecognized tax benefits that would affect the effective tax rate if recognized	71,000,000	69,000,000
Tax interest expense (credit)	1,000,000		$ (2,000,000)
Total interest	14,000,000	12,000,000
Total penalties	$ 0	$ 0

Legal Proceedings - Narrative (Details)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Legal Proceedings - Narrative (Details)	Jun. 30, 2022 USD ($) claims	Sep. 24, 2022 USD ($) claims	Sep. 25, 2021 USD ($)	Sep. 24, 2022 USD ($) claims	Sep. 25, 2021 USD ($)	Dec. 25, 2021 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues \| $		$ 3,067,000,000	$ 3,178,000,000	$ 9,276,000,000	$ 9,070,000,000
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims		150		150
Actions consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage						0.20%
Actions consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues \| $						$ 12,400,000,000
Hospitals in West Virginia [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of claims settled \| claims	26
Number of claims dismissed	26
Additional Hospital [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of claims settled \| claims	1
Litigation settlements \| $	$ 300,000
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs				38
DCH Health Care Authority, et al. [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs				38
Number of plantiffs set for jury trial				8

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 2 months 12 days
Total unrecognized compensation cost related to non-vested awards	$ 104		$ 104
Expected life of options (years)			6 years
After-tax share-based compensation (credit) expense	13	$ 21	$ 34	$ 44
Pre-tax share-based compensation (Credit) expense	$ 17	$ 28	$ 44	$ 58
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Percentage of stock options vest per year			33.33%
Expiration period (in years)			10 years
Time-Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			4 years
Time-Based Restricted Stock Restricted Units [Member] \| 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Special Pandemic Recognition Award [Member] \| 2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			2 years
Stock based compensation percentage of options vest per year first anniversary			50.00%
Stock based compensation percentage of options vest per year second anniversary			50.00%
Cumulative percentage payout based on actual performance and one-time special award			75.00%
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Performance-Based Restricted Stock Units [Member] \| 2020 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage payout based on actual performance			20.00%
Performance-Based Restricted Stock Units [Member] \| 2018 Long-Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Stock-Based Compensation - Assumptions used in Determining Fair Values of Stock Options using the Black-Scholes Valuation Model (Details)	9 Months Ended
	Sep. 24, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected dividend yield	0.00%
Expected stock price volatility	27.70%
Risk-free interest rate	3.42%
Expected life of options (years)	6 years

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 24, 2022
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	767,717
Granted (in shares)	418,425
Exercised (in shares)	(30,554)
Forfeited (in shares)	(17,850)
Outstanding at end of period (in shares)	1,137,738
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 63.24
Granted (in dollars per share)	85.82
Exercised (in dollars per share)	62.71
Forfeited (in dollars per share)	72.96
Outstanding at end of period (in dollars per share)	$ 71.41
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	8 years 9 months 18 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 3
Options exercisable (in shares)	223,198
Weighted average exercise price, options exercisable (in dollars per share)	$ 63.19

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 24, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	898,310
Weighted Average Exercise Price \| $ / shares	$ 73.60
Weighted Average Remaining Contractual Life (in years)	8 years 10 months 24 days
Aggregate Intrinsic Value \| $	$ 2

Stock-Based Compensation - Status of Non-Vested Restricted Shares/Units (Details)	9 Months Ended
	Sep. 24, 2022 $ / shares shares
Time-Based Restricted Stock Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,945,862
Granted (in shares) \| shares	466,473
Vested (in shares) \| shares	(505,004)
Forfeited (in shares) \| shares	(54,618)
Ending balance outstanding (in shares) \| shares	1,852,713
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 58.79
Granted (in dollars per share)	85.67
Vested (in dollars per share)	54.74
Forfeited (in dollars per share)	67.23
Ending balance outstanding (in dollars per share)	66.39
Aggregate intrinsic value	$ 67.34
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	674,753
Granted (in shares) \| shares	442,871
Vested (in shares) \| shares	(392,646)
Forfeited (in shares) \| shares	(13,631)
Ending balance outstanding (in shares) \| shares	711,347
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 59.63
Granted (in dollars per share)	76.68
Vested (in dollars per share)	59.18
Forfeited (in dollars per share)	67.17
Ending balance outstanding (in dollars per share)	63.27
Aggregate intrinsic value	$ 67.34

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 613	$ 328	$ 328
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interest in subsidiaries			(26)		(60)
Increase in redeemable noncontrolling interests due to business acquisitions			4		189
Net income attributable to Redeemable noncontrolling interests	$ 10	$ 5	19	19	23
Dividends declared			(16)		(21)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(6)	$ (5)	(13)	$ (4)	(6)
Change in fair value of redeemable securities			(18)		160
Balance, end of period	$ 563		$ 563		$ 613

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (44)		$ (44)		$ (31)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)		0
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(317)		(317)		(155)
Unrealized gain (loss) from foreign currency hedging activities	18		18		(2)
Pension adjustment loss	(13)		(13)		(14)
Accumulated other comprehensive loss	(312)		(312)		(171)
Total Accumulated other comprehensive income (loss)	(357)		(357)		$ (202)
Components of Comprehensive Income
Net Income (loss)	162	$ 169	515	$ 508
Foreign currency translation loss	(89)	(40)	(176)	(40)
Tax effect	0	0	0	0
Foreign currency translation loss	(89)	(40)	(176)	(40)
Unrealized gain from foreign currency hedging activities	15	5	27	7
Tax effect	(4)	(1)	(7)	(2)
Unrealized gain from foreign currency hedging activities	11	4	20	5
Pension adjustment gain	2	0	2	1
Tax effect	(1)	0	(1)	0
Pension adjustment gain	1	0	1	1
Comprehensive income	$ 85	$ 133	$ 360	$ 474

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 79	$ 131	$ 350	$ 454
Comprehensive income attributable to noncontrolling interests	2	2	4	5
Comprehensive income attributable to Redeemable noncontrolling interests	4	0	6	15
Comprehensive income	$ 85	$ 133	$ 360	$ 474

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Plans of Restructuring and Integration Costs - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 9,000,000	$ 0	$ 9,000,000
Midway Dental Supply [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2,000,000		2,000,000
Integration costs	$ 1,000,000		$ 1,000,000

Plans of Restructuring and Integration Costs - Schedule of Restructuring Reserve by Type of Cost (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 9,000,000	$ 0	$ 9,000,000
Total	10,000,000	$ 0	10,000,000	$ 4,000,000
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total	6,000,000		6,000,000	4,000,000
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Total	2,000,000		2,000,000	0
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total	1,000,000		1,000,000	0
Integration Employee-Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Total	1,000,000		1,000,000	0
Health-Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	9,000,000		9,000,000	3,000,000
Integration Costs	1,000,000		1,000,000	0
Health-Care Distribution [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	6,000,000		6,000,000	3,000,000
Integration Costs	0		0	0
Health-Care Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	2,000,000		2,000,000	0
Integration Costs	0		0	0
Health-Care Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		1,000,000	0
Integration Costs	0		0	0
Health-Care Distribution [Member] \| Integration Employee-Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	0
Integration Costs	1,000,000		1,000,000	0
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	1,000,000
Integration Costs	0		0	0
Technology and Value-Added Services [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	1,000,000
Integration Costs	0		0	0
Technology and Value-Added Services [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	0
Integration Costs	0		0	0
Technology and Value-Added Services [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	0
Integration Costs	0		0	0
Technology and Value-Added Services [Member] \| Integration Employee-Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		0	0
Integration Costs	$ 0		$ 0	$ 0

Plans of Restructuring and Integration Costs - Schedule of Restructuring Reserve by Segment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Restructuring Cost and Reserve [Line Items]
Balance, beginning			$ 4,000,000
Restructuring charges	$ 9,000,000	$ 0	9,000,000
Non-cash charges			(2,000,000)
Payments and other adjustments			(6,000,000)
Balance, ending	5,000,000		5,000,000
Health-Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			3,000,000
Restructuring charges	9,000,000		9,000,000	$ 3,000,000
Non-cash charges			(2,000,000)
Payments and other adjustments			(5,000,000)
Balance, ending	5,000,000		5,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			1,000,000
Restructuring charges	0		0	$ 1,000,000
Non-cash charges			0
Payments and other adjustments			(1,000,000)
Balance, ending	$ 0		$ 0

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Weighted-average common shares outstanding:
Basic (in shares)	135,608,678	139,377,237	136,731,413	140,661,182
Effect of dilutive securities:
Stock options and restricted stock units	1,475,371	1,702,100	1,756,841	1,517,520
Diluted (in shares)	137,084,049	141,079,337	138,488,254	142,178,702

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	927,991	789,130	572,283	601,514
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	482,497	789,130	310,565	595,798
Restricted Stock Units R S U [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS	445,494	0	261,718	5,716

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021
Supplemental Cash Flow Information [Abstract]
Interest			$ 29	$ 22
Income taxes			235	179
Non-cash net unrealized gains related to foreign currency hedging activities	$ 15	$ 5	$ 27	$ 7

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 24, 2022	Sep. 25, 2021	Sep. 24, 2022	Sep. 25, 2021	Dec. 25, 2021
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 72.0		$ 72.0		$ 76.0
Noncurrent operating lease liabilities	271.0		$ 271.0		268.0
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Due to related party	9.0		$ 9.0		9.0
Due from related party	39.0		39.0		45.0
Revenue from Related Parties	16.0	$ 18.0	49.0	$ 51.0
Related Party Transaction, Purchases from Related Party	4.0	5.0	$ 14.0	14.0
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period Covered By Agreement			10 years
Related party agreement amount			$ 31.0
Related Party Transaction, Expenses from Transactions with Related Party	8.0	$ 8.0	23.0	$ 23.0
Related Party Transaction, Due from (to) Related Party	(14.0)		(14.0)		$ 9.0
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	4.0		4.0
Noncurrent operating lease liabilities	$ 16.0		$ 16.0
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Current [Member] \| Lessor Concentration Risk [Member]
Related Party Transaction [Line Items]
Concentration risk percentage			5.20%
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Non-Current [Member] \| Lessor Concentration Risk [Member]
Related Party Transaction [Line Items]
Concentration risk percentage			5.80%
Employees and Minority Shareholders [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	1 year		1 year
Employees and Minority Shareholders [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	9 years		9 years